ArriVent BioPharma (AVBP) PT Raised to $38 at Goldman Sachs
Tweet
Share
E-mailGet Alerts AVBP Hot Sheet
Price: $29.51 -1.63%
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Corinne Johnson raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $38.00 (from $28.00) while maintaining a Buy rating.
You May Also Be Interested In
- Citi cuts ArriVent BioPharma price target to $40
- ArriVent BioPharma Reports Second Quarter 2026 Financial Results
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
